FDA Clears Dendreon Facility

Dendreon recently received clearance from the U.S. Food and Drug Administration to expand manufacturing facility for its cancer vaccine Provenge, in the U.S. The company’s Los Angeles facility can now be operational with 36 workstations.
Zacks